Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
December 21, 2020 07:59 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor
December 02, 2020 13:11 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for...
Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics
November 18, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for...
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin
November 11, 2020 09:10 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
October 26, 2020 09:21 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
October 20, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
September 29, 2020 08:39 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs
September 21, 2020 08:56 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19
September 16, 2020 08:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder
September 02, 2020 08:15 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...